Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Pharmacogenetic Determinant of the Drug Interaction Between Tacrolimus and Omeprazole

Zhao, Wei PharmD, PhD*,†; Fakhoury, May PharmD, PhD*,†; Maisin, Anne MD; Baudouin, Véronique MD; Storme, Thomas PharmD, PhD§; Deschênes, Georges MD, PhD‡,¶; Jacqz-Aigrain, Evelyne MD, PhD*,†,¶

doi: 10.1097/FTD.0b013e318271b6e6
Case Report

Abstract: A 17-year-old adolescent with acute nephrotoxicity had CYP3A4-5, CYP2C19, and ABCB1 genotyping performed to understand a suspected drug interaction between tacrolimus and omeprazole. The determinant role of individual pharmacogenetic profile in the occurrence of tacrolimus nephrotoxicity is presented and discussed.

*AP-HP, Department of Pediatric Pharmacology and Pharmacogenetics, Hôpital Robert Debré

INSERM, Clinical Investigation Center CIC9202

AP-HP, Department of Pediatric Nephrology, Hôpital Robert Debré

§AP-HP, Department of Pharmacy, Hôpital Robert Debré

Université Paris Diderot, Sorbonne Paris Cité, Paris, France.

Correspondence: Wei Zhao, PharmD, PhD, Department of Pediatric Pharmacology and Pharmacogenetics, Hôpital Robert Debré, 48 Boulevard Sérurier, 75935 Paris Cedex 19, France (e-mail:

This work was supported by Global Research in Paediatrics – Network of Excellence (GRIP, EU-funded FP7 project, Grant Agreement number 261060).

The authors declare no conflict of interest.

Received August 22, 2012

Accepted August 29, 2012

© 2012 Lippincott Williams & Wilkins, Inc.